Pharmaceutical

Amylyx axes ALS drug from market after Phase III failure 

Last month, Amylyx announced that the Phase III confirmatory trial of ALS drug Relyvrio failed to meet its primary and secondary endpoints.

Apr 7, 2024 - 00:00
Amylyx axes ALS drug from market after Phase III failure 
Last month, Amylyx announced that the Phase III confirmatory trial of ALS drug Relyvrio failed to meet its primary and secondary endpoints.
Read the original article

Tags:

Previous Article

GSK expands Asia-Pacific reach for Trelegy Ellipta with Singapore approval

Next Article

England’s MMR vaccinations up 23% following NHS initiative

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Blood cancers may arise from CAR-T cells, but experts think only in very rare cases

STAT+: Blood cancers may arise from CAR-T cells, but ex...

Nov 29, 2023

Leprosy potentially endemic in Central Florida

Leprosy potentially endemic in Central Florida

Aug 16, 2023

Lead aprons not necessary for patients during X-rays, says largest U.S. dental group

Lead aprons not necessary for patients during X-rays, s...

Feb 3, 2024